6月25日，艾伯维公司盘中上涨3.23%，报242.47美元/股，成交额3.75亿美元。
消息面上，艾伯维近日宣布以约109亿美元全现金收购Apogee Therapeutics，获取其核心资产zumilokibart（靶向IL-13的长效单抗），强化免疫学管线布局。瑞银认为该收购对zumilokibart估值"充分且合理"，该药已进入三期开发，具备"超级重磅炸弹"潜力。Canaccord Genuity随后将艾伯维目标价从265美元上调至273美元，维持买入评级。此外，艾伯维旗下Skyrizi获欧盟批准用于儿童银屑病、Maviret获批用于急性丙肝治疗，旗下艾尔建美学新品Boey在加拿大获批，多重产品线利好共同提振市场信心。交易预计三季度完成，反垄断风险有限。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.